I would think so, though IV/sub-q held up quite well even with Tyvaso on the market and I believe it was Dr. Rubin who believe an Inhaled therapy would be the best way to treat the disease.
From an investment standpoint I think Oral in other indications may have the biggest potential. UTHR has tried/talked about Remodulin for other uses for some time and I'm not a science guy but a Prostacylin makes some sense in other cardiovascular indications.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.